Health Care Related Organization
Women Breaking Barriers in Drug Development: Celebrating Leadership and Innovation
Women in drug development, gender equity, STEM, pharmaceutical industry, leadership, innovation
Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials
Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials
QIAGEN and AstraZeneca Enhance Partnership to Develop Companion Diagnostics for Chronic Diseases
QIAGEN, AstraZeneca, companion diagnostics, chronic diseases, precision medicine, QIAstat-Dx, genotyping assay
The Post-Chevron Regulatory Landscape: Implications for the FDA and Healthcare Industry
Chevron deference, FDA, regulatory landscape, healthcare industry, Supreme Court ruling, Loper Bright Enterprises v. Raimondo, Corner Post, Inc. v. Board of Governors of the Federal Reserve System, Administrative Procedure Act (APA), judicial scrutiny, legal challenges, regulatory implications.
Catalent’s Revival: Are the Dark Days Behind It Ahead of Novo Holdings Acquisition?
Catalent, Novo Holdings, acquisition, pharmaceutical industry, revenue boost, dark days, revival
Future-Proofing Healthcare: Inclusive and Protective Patient Strategies
future-proofing, inclusive healthcare, patient-centered care, digital patient experience, data linkage, clinical trials, health and safety programs
Regeneron Takes Legal Action Against Sandoz to Block Eylea Biosimilar
Regeneron, Sandoz, Eylea, biosimilar, lawsuit, patent infringement
Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases
Pfizer, Flagship Pioneering, Quotient Therapeutics, cardiovascular diseases, renal diseases, somatic genomics, drug development, partnership
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
Genentech Announces 93 Layoffs in California Following Closure of Cancer Immunology Research Unit
Genentech, layoffs, California, cancer immunology research unit, biotech, workforce reduction